歐洲全基因組和EXOME定序市場：按最終用戶和國家分析和預測（2024-2033）

預計到 2033 年，歐洲全基因組和EXOME定序市場規模將從 2024 年的 5.49 億美元達到 17.773 億美元，預測期內的複合年成長率為 13.94%。

EXOME定序（WES）和全基因測序（WGS）是徹底改變歐洲基因分析的尖端基因組技術。 WGS 對整個基因組進行定序，包括轉錄區和非編碼區域，而 WES 僅針對蛋白質編碼外顯子，其中包含大多數與疾病相關的突變。這些技術正在徹底改變臨床診斷、個人化醫療和罕見疾病研究，推動醫療創新。隨著技術不斷進步、成本下降和應用範圍不斷擴大，WGS 和 WES 正成為歐洲基因體學的重要工具。

由於個人化醫療需求的不斷成長、臨床診斷應用的不斷成長以及基因組研究的不斷改進，歐洲全基因組和EXOME定序市場正在顯著成長。EXOME定序（WES）主要針對蛋白質轉錄區，大多數已知的疾病相關突變都存在於該區域，而全基因測序（WGS）則可以深入了解一個人的完整基因組成。這些技術正在透過促進早期疾病檢測、精準醫療和更好地了解遺傳疾病來改變醫療產業。

對 WGS 和 WES 的需求是由於癌症、神經系統疾病和罕見疾病的發生率不斷上升，尤其是在臨床和研究環境中。政府對基因組醫學的資助和舉措以及生物技術公司和醫療機構之間的合作也推動了市場擴張。此外，定序技術的不斷改進正在降低成本並使這些先進的工具更容易獲得。

歐洲擁有嚴格的法律規範，確保資料準確性和患者安全，並處於基因組創新的前沿。腫瘤學、感染疾病研究和生殖醫學領域應用的不斷擴大也促進了市場的成長。隨著基因測序的不斷發展，它將在未來整個歐洲的精準醫療和生物醫學研究中發揮關鍵作用。

市場區隔

細分 1：按最終用戶

• 製藥和生物技術公司
• 診斷實驗室
• 醫院和診所
• 研究和學術機構
• 其他

細分2：按地區

• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
  • 其他

本報告研究了歐洲全基因組和EXOME定序市場，並提供了主要趨勢的摘要、影響市場的因素的分析、法律制度、市場規模趨勢和預測、各個細分市場和主要國家的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章 產業展望

• 市場趨勢
  • 定序技術的創新
  • 市場上有大量無機成長活動
• COVID-19 對市場的影響
• 法律規範
  • 歐洲法律要求和框架
• 供應鏈分析
• 市場動態概覽
  • 市場促進因素
  • 市場限制
  • 市場機會

第2章 區域

• 區域概況
• 歐洲
  • 區域概況
  • 市場成長動力
  • 市場問題
  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 荷蘭
  • 其他

第 3 章市場：競爭基準化分析與公司簡介

• 主要策略及發展
• 企業市場占有率分析
• 公司簡介
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Oxford Nanopore Technologies plc
  • QIAGEN NV

第4章調查方法

Introduction to Europe Whole Genome and Exome Sequencing Market

The Europe whole genome and exome sequencing market is projected to reach $1,777.3 million by 2033 from $549.0 million in 2024, growing at a CAGR of 13.94% during the forecast period 2024-2033. Exome sequencing (WES) and whole genome sequencing (WGS) are cutting-edge genomic technologies that are revolutionising genetic analysis in Europe. WGS decodes the entire genome, including coding and non-coding regions, while WES only targets protein-coding exons, which contain the majority of disease-related variants. These techniques are boosting healthcare innovation by revolutionising clinical diagnostics, personalised medicine, and rare disease research. As technology continues to advance, costs come down, and their applications expand, WGS and WES are becoming indispensable tools in European genomics.

Market Introduction

The market for whole genome and exome sequencing in Europe is expanding significantly due to the growing demand for personalised medicine, growing adoption of clinical diagnostics, and improvements in genomic research. Exome sequencing (WES) concentrates on protein-coding regions, which are home to the majority of known disease-related variants, whereas whole genome sequencing (WGS) offers a thorough examination of a person's complete genetic composition. By facilitating early disease detection, precision treatment, and a better understanding of genetic disorders, these technologies are transforming the healthcare industry.

The need for WGS and WES has increased due to the rising incidence of cancer, neurological disorders, and rare diseases, especially in clinical and research settings. Market expansion is also being aided by government funding and initiatives for genomic medicine, as well as partnerships between biotech companies and healthcare organizations. Additionally, ongoing improvements in sequencing technology are reducing costs, making these advanced tools more accessible.

With stringent regulatory frameworks ensuring data accuracy and patient safety, Europe is at the forefront of genomic innovation. Expanding applications in oncology, infectious disease research, and reproductive health are also contributing to market growth. As genomic sequencing continues to evolve, it is set to play a crucial role in the future of precision medicine and biomedical research across Europe.

Market Segmentation

Segmentation 1: by End User

• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• Hospitals and Clinics
• Research and Academic Institutes
• Others

Segmentation 2: by Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements and emerging applications in genome and exome sequencing, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd
• Oxford Nanopore Technologies plc
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Industry Outlook

• 1.1 Market Trends
  • 1.1.1 Technological Innovations in the Sequencing Technology
  • 1.1.2 Numerous Inorganic Growth Activities in the Market
• 1.2 COVID-19 Impact on Market
• 1.3 Regulatory Framework
  • 1.3.1 Legal Requirements and Framework in Europe
• 1.4 Supply Chain Analysis
• 1.5 Market Dynamics Overview
  • 1.5.1 Market Drivers
    • 1.5.1.1 Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics
    • 1.5.1.2 Rising Demand for Personalized Medicine Influencing the Demand for Whole Genome and Exome Sequencing
    • 1.5.1.3 Lowering Costs and Increasing Accessibility of Genome Sequencing
    • 1.5.1.4 Ongoing Whole Genome Sequencing Government Initiatives around the World
  • 1.5.2 Market Restraints
    • 1.5.2.1 Privacy and Ethical Concerns due to Increased Risk of Security Breaches
  • 1.5.3 Market Opportunities
    • 1.5.3.1 Increasing Usage of Sequencing Technology in Emerging Markets

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
    • 2.2.3.1 By End User
  • 2.2.4 France
  • 2.2.5 Germany
  • 2.2.6 U.K.
  • 2.2.7 Spain
  • 2.2.8 Italy
  • 2.2.9 Netherlands
  • 2.2.10 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Key Strategies and Development
• 3.2 Company Share Analysis
• 3.3 Company Profiles
  • 3.3.1 Eurofins Scientific SE
    • 3.3.1.1 Overview
    • 3.3.1.2 Top Products
    • 3.3.1.3 Top Competitors
    • 3.3.1.4 Key Personnel
    • 3.3.1.5 Analyst View
  • 3.3.2 F. Hoffmann-La Roche Ltd
    • 3.3.2.1 Overview
    • 3.3.2.2 Top Products
    • 3.3.2.3 Top Competitors
    • 3.3.2.4 Key Personnel
    • 3.3.2.5 Analyst View
  • 3.3.3 Oxford Nanopore Technologies plc
    • 3.3.3.1 Overview
    • 3.3.3.2 Top Products
    • 3.3.3.3 Top Competitors
    • 3.3.3.4 Key Personnel
    • 3.3.3.5 Analyst View
  • 3.3.4 QIAGEN N.V.
    • 3.3.4.1 Overview
    • 3.3.4.2 Top Products
    • 3.3.4.3 Top Competitors
    • 3.3.4.4 Key Personnel
    • 3.3.4.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023, 2026, and 2033
• Figure 2: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023, 2026, and 2033
• Figure 3: Key Events to Keep Track of within the Whole Genome and Exome Sequencing Market
• Figure 4: Value and Supply Chain Analysis, Whole Genome and Exome Sequencing Market
• Figure 5: Analysis of Market Navigating Factors, 2023-2033
• Figure 6: Key Clinical Applications of Whole Genome and Whole Exome Sequencing
• Figure 7: Number of Research Papers Mentioning Personalized Medicine in PubMed, 2010-2023
• Figure 8: Decreasing Genome Sequencing Costs
• Figure 9: Map of a Few Recent and Ongoing Government-Funded National Genomic-Medicine Initiatives
• Figure 10: Examples of Security Breaches in Whole Genome and Exome Sequencing
• Figure 11: France Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 12: Germany Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 13: U.K. Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 14: Spain Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 15: Italy Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 16: Netherlands Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 17: Rest-of-Europe Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 18: Strategic Initiatives, January 2021-April 2024
• Figure 19: Share of Strategic Initiatives, January 2021-April 2024
• Figure 20: Whole Genome and Exome Sequencing Market, Company Revenue Share Analysis, 2023
• Figure 21: Data Triangulation
• Figure 22: Top-Down and Bottom-Up Approach
• Figure 23: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Opportunities across Regions
• Table 3: Recent Technological Innovations
• Table 4: Few Major Inorganic Growth Activities in the Whole Genome and Exome Sequencing Market
• Table 5: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023-2033
• Table 6: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033